• Arina Windri Rivarti University of Mataram




sea urchin, DHA, omega-3, dementia


With the increasing prevalence of Alzheimer's dementia and the lack of effectiveness of existing drugs in inhibiting the progression of the disease, the investigation of new drug candidates will continue. Omega-3 fatty acids, especially docosahexaenoic acid (DHA), are compounds that can be used as drug candidates for this purpose. Recent scientific evidence, both from epidemiological studies and preclinical trials in experimental animals, shows the potential of these compounds in maintaining cognitive function and inhibiting the progression of Alzheimer's dementia through various mechanisms, including anti-inflammatory, anti-amyloidogenic, and brain neuroplasticity. These compounds are contained in various marine organisms, including sea urchins. Given the wide availability of marine life on the coast and its ability to biosynthesis of omega-3 fatty acids, this marine biota can be considered as the main source of omega-3 in the development of omega-3 as a drug for the protection of cognitive function in Alzheimer's disease dementia.


1. Fishman E. Risk of developing dementia at older ages in the United States. Demography. 2017; 54: 1897-1919.
2. Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022; 7: e105-25.
3. Dou K-X, Tan M-S, Tan C-C, Cao X-P, Hou X-H, Guo Q-H, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta- analysis of 41 randomized controlled trials. Alzheimer's Research & Therapy. 2018; 10: 126.
4. Avallone R, Vitale G, Bertolotti M. Omega-3 fatty acids and neurodegenerative diseases: new evidence in clinical trials. Int J Mol Sci. 2019; 20: 4256.
5. Chu C-S, Hung C-F, Ponnusamy VK, Chen K-C, Chen N-C. Higher serum DHA and slower cognitive decline in patients with Alzheimer’s disease: two-year follow-up. Nutrients. 2022; 14: 1159.
6. van Lent DM, Egert S, Wolfsgruber S, Kleineidam L, Weinhold L, Wagner-Thelen H, et al. Eicosapentaenoic acid is associated with decreased incidence of Alzheimer’s dementia in the oldest old. Nutrients. 2021;13: 461.
7. Thomas A, Baillet M, Proust-Lima C, Feart C, Foubert-Samier A, Helmer C, Catheline G, Samieri C. Blood polyunsaturated omega-3 fatty acids, brain atrophy, cognitive decline, and dementia risk. Alzheimers Dement. 2020; 17: 407–416.
8. Hopperton KE, Trepanier M-O, Giuliano V, Bazinet RP. Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-? 1-40 in mice. Journal of Neuroinflammation. 2016; 13: 257.
9. Aziz NA, Azlan A, Ismail A, Alinafiah SM, Razman MR. Quantitative determination of fatty acids in marine fish and shellfish from warm water of straits of malacca for nutraceutical purposes. BioMed Research International. 2013; 2013: 284329.
10. Luczynska J, Paszczyk B, Luczynski MJ. Fatty acid profiles in marine and freshwater fish from fish markets in northeastern Poland. Arch Pol Fish. 2014; 22: 181-88.
11. Mejri SC, Tremblay R, Audet C, Wills PS, Riche M. Essential fatty acid requirements in tropical and cold-water marine fish larvae and juveniles. Front Mar Sci. 2021; 8: 680003.
12. Kim HDT, Quoc LP, Nguyen PH, Lan PD, Dinh TT. Research on the component of lipid classes, fatty acid from egg and body of sea urchin Diadema savignyi (Audouin, 1809). Journal of Pharmacognosy and Phytochemistry. 2018; 7(1): 836-40.
13. Kabeya N, Sanz-Jorquera A, Carboni S, Davie A, Oboh A, Monroig O. Biosynthesis of Polyunsaturated Fatty Acids in Sea Urchins: Molecular and Functional Characterisation of Three Fatty Acyl Desaturases from Paracentrotus lividus (Lamark 1816). PLoS ONE. 2017; 12(1): e0169374.
14. Zhao Q, Zhou B, Ding D, Teramukai S, Guo Q, Fukushima M, Hong Z. Cognitive decline in patients with Alzheimer’s disease and its related factors in a memory clinic setting, Shanghai, China. PLoS ONE. 2014; 9(4): e95755.
15. Wong W. Economic burden of Alzheimer disease and managed care considerations. Am J Manag Care. 2020;26(8 Suppl): S177-S183.
16. Medrano M, Rosario RL, Payano AN, Capellan NR. Burden, anxiety and depression in caregivers of Alzheimer patients in the Dominican Republic. Dementia & Neuropsychologia. 2014; 8(4): 384-8.
17. Vespa A, Spatuzzi R, Fabbietti P, Penna M, Giulietti MV. Association between care burden, depression and personality traits in Alzheimer’s caregiver: A pilot study. PLoS ONE. 2021; 16(9): e0251813.
18. Pinyopornpanish M, Pinyopornpanish K, Soontornpun A, Tanprawate S, Nadsasarn A, Wongpakaran N, et al. Perceived stress and depressive symptoms not neuropsychiatric symptoms predict caregiver burden in Alzheimer’s disease: a cross-sectional study. BMC Geriatrics. 2021; 21: 180.
19. Shaji KS, Sivakumar PT, Rao GP, Paul N. Clinical Practice Guidelines for Management of Dementia. Indian J Psychiatry. 2018; 60(Suppl 3): S312-S328. doi:10.4103/0019-5545.224472
20. Devassy JG, Leng S, Gabbs M, Monirujjaman M, Aukema HM. Omega-3 Polyunsaturated fatty acids and oxylipins in neuroinflammation and management of Alzheimer disease. Adv Nutr 2016; 7: 905–16.
21. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396: 413-46.
22. Fan L, Mao C, Hu X, Zhang S, Yang Z, Hu Z, et al. New insights into the pathogenesis of Alzheimer’s disease. Front. Neurol. 2020; 10: 1312.
23. Beason-Held LL, Goh JO, An Y, Kraut MA, O’Brien RJ, Ferrucci L, et al. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci. 2013; 33(46): 18008-18014.
24. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. International Journal of Nanomedicine. 2019; 14: 5541-54.
25. Thakur AK, Kamboj P, Goswami K, Ahuja K. Pathophysiology and management of alzheimer’s disease: an overview. J Anal Pharm Res. 2018; 7(2): 226-35.
26. Barbier P, Zejneli O, Martinho M, Lasorsa A, Belle V, Smet-Nocca C, et al. Role of tau as a microtubule-associated protein: structural and functional aspects. Front. Aging Neurosci. 2019; 11: 204.
27. Cholewski M, Tomczykowa M, Tomczyk M. A Comprehensive review of chemistry, sources and
bioavailability of omega-3 fatty acids. Nutrients. 2018; 10: 1662.
28. Burri L, Hoem N, Banni S, Berge K. Marine omega-3 phospholipids: metabolism and
biological activities. Int J Mol Sci. 2013; 13: 15401-19.
29. Xiao M, Xiang W, Chen Y, Peng N, Du X, Lu S, et al. DHA ameliorates cognitive ability, reduces amyloid deposition, and nerve fiber production in Alzheimer’s disease. Front Nutr. 2022; 9:852433.
30. Kim H-Y. Spector AA. Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. Prostaglandins Leukot Essent Fatty Acids. 2013; 88(1): 121-5.
31. Alrajab M, Shulgina LV. Dietary product based on sea urchin caviar and Sardinops melanostictus fat. Journal of Applied Biology & Biotechnology. 2022; 10(5): 102-6.




How to Cite

Rivarti, A. W. (2022). POTENSI OMEGA-3 BULU BABI (SEA URCHIN) DALAM KONTROL PROGRESIVITAS DEMENSIA ALZHEIMER. Jurnal Kedokteran, 11(4), 1213–1218. https://doi.org/10.29303/jku.v11i4.838



Literature Review

Most read articles by the same author(s)